Cargando…

What Can We Learn from the Evolution of Protein-Ligand Interactions to Aid the Design of New Therapeutics?

Efforts to increase affinity in the design of new therapeutic molecules have tended to lead to greater lipophilicity, a factor that is generally agreed to be contributing to the low success rate of new drug candidates. Our aim is to provide a structural perspective to the study of lipophilic efficie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Higueruelo, Alicia P., Schreyer, Adrian, Bickerton, G. Richard J, Blundell, Tom L., Pitt, Will R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3519888/ https://www.ncbi.nlm.nih.gov/pubmed/23240060 http://dx.doi.org/10.1371/journal.pone.0051742

Ejemplares similares

Comprehensive, atomic-level characterization of structurally characterized protein-protein interactions: the PICCOLO database
por: Bickerton, George R, et al.
Publicado: (2011)

TIMBAL v2: update of a database holding small molecules modulating protein–protein interactions
por: Higueruelo, Alicia P., et al.
Publicado: (2013)

Arpeggio: A Web Server for Calculating and Visualising Interatomic Interactions in Protein Structures
por: Jubb, Harry C, et al.
Publicado: (2017)

TIBLE: a web-based, freely accessible resource for small-molecule binding data for mycobacterial species
por: Malhotra, Sony, et al.
Publicado: (2017)

Does a More Precise Chemical Description of Protein–Ligand Complexes Lead to More Accurate Prediction of Binding Affinity?
por: Ballester, Pedro J., et al.
Publicado: (2014)

On the Origins of Enzyme Inhibitor Selectivity and Promiscuity: A Case Study of Protein Kinase Binding to Staurosporine
por: Tanramluk, Duangrudee, et al.
Publicado: (2009)

Molecular Design of Luminescent Complexes of Eu(III): What Can We Learn from the Ligands
por: Romanova, Julia, et al.
Publicado: (2023)

Why Is Aging Conserved and What Can We Do about It?
por: Pitt, Jason N., et al.
Publicado: (2015)

Correction: Why Is Aging Conserved and What Can We Do about it?
por: Pitt, Jason N., et al.
Publicado: (2015)

USRCAT: real-time ultrafast shape recognition with pharmacophoric constraints
por: Schreyer, Adrian M, et al.
Publicado: (2012)

What can we predict about viral evolution and emergence?
por: Holmes, Edward C
Publicado: (2013)

WHAT CAN WE ACTUALLY SEE USING COMPUTER AIDED DETECTION IN MAMMOGRAPHY?
por: Džoić Dominković, Martina, et al.
Publicado: (2020)

CREDO: a structural interactomics database for drug discovery
por: Schreyer, Adrian M., et al.
Publicado: (2013)

High-energy resolution X-ray spectroscopy at actinide M(4,5) and ligand K edges: what we know, what we want to know, and what we can know
por: Kvashnina, Kristina O., et al.
Publicado: (2021)

Biomedical nanoparticle design: What we can learn from viruses
por: Maslanka Figueroa, Sara, et al.
Publicado: (2021)

What Can We Demonstrate?
por: Mills, G. A.
Publicado: (1896)

Reversal Agents: What We Have and What We Can Expect
por: Ruff, Christian T.
Publicado: (2018)

Enhancer RNA: What we know and what we can achieve
por: Han, Zhenzhen, et al.
Publicado: (2022)

What we can and what we cannot see with extracellular multielectrodes
por: Chintaluri, Chaitanya, et al.
Publicado: (2021)

The origin of life: what we know, what we can know and what we will never know
por: Pross, Addy, et al.
Publicado: (2013)

What Can We Learn from the Time Evolution of COVID‐19 Epidemic in Slovenia?
por: Bâldea, Ioan
Publicado: (2021)

Quasicrystals: What do we know? What do we want to know? What can we know?
por: Steurer, Walter
Publicado: (2018)

How we remember what we can do
por: Declerck, Gunnar
Publicado: (2015)

What we still don't know about AIDS
por: Robertson, Miranda
Publicado: (2009)

Bone hydration: How we can evaluate it, what can it tell us, and is it an effective therapeutic target?
por: Surowiec, Rachel K., et al.
Publicado: (2021)

What Can We Do to Be Saved?
por: Visanska, Samuel A.
Publicado: (1913)

What can we teach Lymnaea and what can Lymnaea teach us?
por: Rivi, Veronica, et al.
Publicado: (2021)

INDIAN PSYCHIATRY AT THE CROSSROADS - WHAT WE CAN DO WITH WHAT WE HAVE?1
por: Channabasavanna, S.M.
Publicado: (1992)

The cancer-obesity connection: what do we know and what can we do?
por: Riboli, Elio
Publicado: (2014)

Management of Achilles and patellar tendinopathy: what we know, what we can do
por: Aicale, Rocco, et al.
Publicado: (2020)

Isolated Nocturnal Hypertension: What Do We Know and What Can We Do?
por: Tadic, Marijana, et al.
Publicado: (2020)

Hepatitis of unknown etiology in children: What we know and what we can do?
por: Zhu, Mingyu, et al.
Publicado: (2022)

Ketamine plus Alcohol: What We Know and What We Can Expect about This
por: Kobayashi, Natalia Harumi Correa, et al.
Publicado: (2022)

Geriatric Radiation Oncology: What We Know and What Can We Do Better?
por: Roeder, Falk, et al.
Publicado: (2023)

The FIRE AND ICE Trial: What We Know, What We Can Still Learn, and What We Need to Address in the Future
por: Kuck, Karl‐Heinz, et al.
Publicado: (2018)

What can we learn from molecular dynamics simulations for GPCR drug design?
por: Tautermann, Christofer S., et al.
Publicado: (2014)

Rational, computer-aided design of multi-target ligands
por: Achenbach, J, et al.
Publicado: (2011)

Coccidioidomycosis and Host Microbiome Interactions: What We Know and What We Can Infer from Other Respiratory Infections
por: Tejeda-Garibay, Susana, et al.
Publicado: (2023)

Cosmic debris: what it is and what we can do about it
por: Powell, Jonathan
Publicado: (2017)

What can we learn from rapidly developed patient decision aids produced during the covid-19 pandemic?
por: Barry, Michael J, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c0rk830b8s5qrcm4ku72lo8v3u